Drug Type Small molecule drug |
Synonyms Barasertib-HQPA |
Target |
Mechanism Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors) |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC26H31FN7O6P |
InChIKeyGBJVVSCPOBPEIT-UHFFFAOYSA-N |
CAS Registry722543-31-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | US | 22 Mar 2024 | |
Relapsing acute myeloid leukemia | Preclinical | IT | 01 May 2006 | |
Relapsing acute myeloid leukemia | Preclinical | FR | 01 May 2006 | |
Advanced Malignant Solid Neoplasm | Preclinical | NL | 01 May 2005 | |
Acute Myeloid Leukemia | Preclinical | - | - | |
Acute Myeloid Leukemia | Preclinical | - | - | |
Diffuse Large B-Cell Lymphoma | Preclinical | - | - | |
Relapsing acute myeloid leukemia | Discovery | NL | 01 May 2006 | |
Relapsing acute myeloid leukemia | Discovery | US | 01 May 2006 |
Phase 2/3 | 74 | (AZD1152 1200mg) | htgmngqvrx(lwughugecl) = pgzbxcfrvv dxhixvnvko (mxjnbfiogl, rgzrofmhuy - zjgesycoek) View more | - | 31 Mar 2014 | ||
(LDAC 20mg) | htgmngqvrx(lwughugecl) = vfrodatmzb dxhixvnvko (mxjnbfiogl, umhfeqqztv - jceheszsnt) View more |